Intellia Therapeutics, Inc. (CIK: 0001652130) EDGAR, Information, Filings... CompaniesBIO.Com

Intellia Therapeutics, Inc.

Mailing address
40 ERIE STREET, SUITE 130, CAMBRIDGE, Delaware, 02139
Phone
857-285-6200
State location
Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2835 - (CF Office: Office of Life Sciences) IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Filings
N/A

Intellia Therapeutics, Inc. (CIK: 0001652130) is an American company incorporated in the state of Massachusetts. Head office is located at 40 ERIE STREET, SUITE 130, CAMBRIDGE, Massachusetts, 02139. Work in the industry 2835 - (CF Office: Office of Life Sciences) IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES. Intellia Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
CHASE WILLIAM J	0001563572	Apr-14-2023	director
Bhanji Muna	0001846905	Apr-28-2022	director
Clark Eliana	0001914448	Feb-23-2022	officer: EVP, Chief Technical Officer
Hicks Derek	0001901282	Dec-20-2021	officer: EVP, Chief Business Officer
Keresty Georgia	0001773532	Jun-23-2021	director
BASTA JAMES	0001792726	Jun-23-2021	officer: EVP, General Counsel
Crowley John F	0001400973	Oct-02-2020	director
Lebwohl David	0001810882	Apr-30-2020	officer: EVP, Chief Medical Officer
LEONARD JOHN M.	0001563584	Mar-02-2020	director, officer: President and CEO
Rivera Jose E	0001671870	Mar-02-2020	officer: EVP, General Counsel
Sepp-Lorenzino Laura	0001777421	Mar-02-2020	officer: EVP, Chief Scientific Officer
SCHIERMEIER ANDREW	0001738456	Jan-03-2020	officer: EVP, Chief Operating Officer
Cohen Fred E	0001339358	Jan-23-2019	director
NOVARTIS AG	0001114448	Dec-31-2018	10 percent owner
Novartis Institutes for BioMedical Research, Inc.	0001673852	Dec-31-2018	10 percent owner
Goddard Glenn	0001581992	Oct-29-2018	officer: See Remarks
GOODMAN JESSE	0001756929	Oct-29-2018	director
HAYES JOHN T.	0001749771	Aug-03-2018	officer: See Remarks
Verwiel Frank	0001545794	Jul-24-2017	director
Slaoui Moncef	0001712369	Jul-24-2017	director
FORMELA JEAN FRANCOIS	0001030575	Jul-07-2017	director
Atlas Venture Associates IX, LLC	0001671207	Jul-07-2017	10 percent owner
Atlas Venture Associates IX, L.P.	0001671208	Jul-07-2017	10 percent owner
Atlas Venture Fund IX, L.P.	0001671219	Jul-07-2017	10 percent owner
Bell Graeme	0001643757	Dec-12-2016	officer: EVP, Chief Financial Officer
Temasek Holdings (Private) Ltd	0001021944	May-05-2016	10 percent owner
ISALY SAMUEL D	0001055949	May-05-2016	10 percent owner
ORBIMED ADVISORS LLC	0001055951	May-05-2016	10 percent owner
BAKER JULIAN	0001087939	May-05-2016	10 percent owner
BAKER FELIX	0001087940	May-05-2016	10 percent owner
DORSA CAROLINE	0001181174	May-05-2016	director
KARSEN PERRY A	0001260573	May-05-2016	director
BAKER BROS. ADVISORS LP	0001263508	May-05-2016	10 percent owner
GORDON CARL L	0001282930	May-05-2016	director, 10 percent owner
Bermingham Nessan	0001377759	May-05-2016	director, 10 percent owner, officer: President & CEO
Fullerton Management Pte Ltd	0001379348	May-05-2016	10 percent owner
Temasek Life Sciences Private Ltd	0001379349	May-05-2016	10 percent owner
Srivastava Sapna	0001569226	May-05-2016	officer: Chief Financial & Stategy Offr
Baker Bros. Advisors (GP) LLC	0001580575	May-05-2016	10 percent owner
Tananbaum James B.	0001581754	May-05-2016	10 percent owner
OrbiMed Capital GP V LLC	0001615374	May-05-2016	10 percent owner
Caribou Biosciences, Inc.	0001619856	May-05-2016	10 percent owner
Foresite Capital Management III, LLC	0001645157	May-05-2016	10 percent owner
Foresite Capital Fund III, L.P.	0001645158	May-05-2016	10 percent owner
Barnes Thomas M.	0001670577	May-05-2016	officer: Chief Scientific Officer
Haurwitz Rachel E.	0001670579	May-05-2016	director, 10 percent owner
Morrissey David V	0001670998	May-05-2016	officer: Chief Technology Officer
Heifner Nicole	0001670999	May-05-2016	officer: Principal Accounting Officer
Caribou Therapeutics Holdco, LLC	0001671465	May-05-2016	10 percent owner
TLS Beta Pte. Ltd.	0001673754	May-05-2016	10 percent owner
OrbiMed Global Healthcare GP LLC	0001673892	May-05-2016	10 percent owner

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Intellia Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
8-K	Document	Current report filing Acc-no: 0001193125-24-168545 (34 Act) Size: 509 KB	Jun-26-2024	001-37766 241070663
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-075718 ( Act) Size: 4 KB	Jun-20-2024
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0000950170-24-074387 ( Act) Size: 12 KB	Jun-17-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-074383 ( Act) Size: 6 KB	Jun-17-2024
8-K	Document	Current report filing Acc-no: 0000950170-24-073709 (34 Act) Size: 198 KB	Jun-14-2024	001-37766 241045206
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073704 ( Act) Size: 6 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073702 ( Act) Size: 6 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073700 ( Act) Size: 6 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073689 ( Act) Size: 6 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073685 ( Act) Size: 6 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073680 ( Act) Size: 6 KB	Jun-14-2024
8-K	Document	Current report filing Acc-no: 0000950170-24-073116 (34 Act) Size: 230 KB	Jun-13-2024	001-37766 241042008
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-057046 (34 Act) Size: 7416 KB	May-09-2024	001-37766 24931130
8-K	Document	Current report filing Acc-no: 0000950170-24-056286 (34 Act) Size: 304 KB	May-09-2024	001-37766 24928612
ARS	Document	Annual report to security holders Acc-no: 0001193125-24-122499 (34 Act) Size: 1204 KB	Apr-29-2024	001-37766 24891548
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0000950170-24-049909 (34 Act) Size: 5513 KB	Apr-29-2024	001-37766 24891289
DEF 14A	Document	Definitive proxy statements Acc-no: 0000950170-24-049875 (34 Act) Size: 4225 KB	Apr-29-2024	001-37766 24891011
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0000950170-24-046423 ( Act) Size: 13 KB	Apr-22-2024
PRE 14A	Document	Preliminary proxy statement not related to a contested matter or merger/acquisition Acc-no: 0000950170-24-044774 (34 Act) Size: 4236 KB	Apr-16-2024	001-37766 24847916
8-K	Document	Current report filing Acc-no: 0000950170-24-044424 (34 Act) Size: 191 KB	Apr-15-2024	001-37766 24844902

Recent 20 filings. View all Intellia Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Intellia Therapeutics, Inc. overview
Intellia Therapeutics, Inc. job
Intellia Therapeutics, Inc. stock
Intellia Therapeutics, Inc. ownership
Intellia Therapeutics, Inc. CEO
Intellia Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.